Announcement PDF LTR Pharma secures 33% ownership in LevOmega Pty Ltd 22 September 2025 Highlights • LTR Pharma secures a 33% equity stake in LevOmega at nil cost to shareholders. • LevOmega co-founded by Levur, Green Blue Health and LTR Pharma, bringing complementary expertise in biotechnology, nutraceuticals, and pharmaceutical commercialisation. • LevOmega enters R&D Services and Licensing Agreement with Levur to develop nature-identical, pharmaceutical-grade omega-3 oil. • Provides LTR with exposure to the multi-billion-dollar global omega-3 market, complementary to its core intranasal pharmaceutical programs. • Synergistic with LTR’s strategy of developing first-in-class therapies for large markets with unmet needs. LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company) is pleased to announce it has secured a onethird equity ownership in LevOmega Pty Ltd at nil cost to LTR Pharma shareholders. This ownership recognises LTR’s leadership and commercial expertise, with no upfront capital required for the one-third stake. LevOmega Pty Ltd has been co-founded by Levur Pty Ltd, Green Blue Health Pty Ltd, and LTR Pharma. Each cofounder contributes distinct strengths – Levur in innovation and product development, Green Blue Health in nutraceutical and health market experience, and LTR pharma in pharmaceutical, regulatory, and commercial capability. LevOmega is an Australian operating company focused on the development of nature-identical omega-3 products. Its mission is to deliver high-purity, consistent omega-3 ingredients that can be used in both nutritional and pharmaceutical applications. By combining expertise in biotechnology, formulation, and pharmaceutical development, LevOmega aims to meet the growing global demand for sustainable and clinically validated omega3 solutions. For investors, this structure ensures LTR Pharma can participate in a high-growth market opportunity as another first-in-class product. R&D Services and Licensing Agreement LevOmega Pty Ltd has formally entered into an R&D Services and Licensing Agreement with Levur Pty Ltd. Under this agreement, Levur will provide specialist R&D services and license its proprietary advanced biotechnology platform to LevOmega to advance the development of nature-identical, pharmaceutical-grade Omega-3 oil. This agreement marks the formal commencement of LevOmega’s development program, a key milestone for the Company and its shareholders. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Addressing a Global Unmet Need Omega-3 oil is widely recognised for its cardiovascular and anti-inflammatory health benefits. However, the current reliance on marine harvesting to meet demand is under increasing strain due to overfishing, pollution, and declining yields. Studies note that global nutritional requirements for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) already exceed sustainable marine supply, and environmental changes continue to affect quality and consistency.1 As a result, demand for nature-identical omega-3 products is expected to rise sharply. Traditional fish oil sources are becoming less reliable and consistent due to worsening global ocean conditions, underscoring the need for scalable, sustainable alternatives. Alignment with LTR’s Strategy This structure extends LTR Pharma’s innovation platform by leveraging its proven ability to develop first-in-class products for large healthcare markets. • SPONTAN® and ROXUS®: first-in-class, rapid-acting nasal sprays for erectile dysfunction. • OROFLOW®: novel treatment in development for oesophageal motility disorders. • LevOmega: pharmaceutical-grade omega-3 ingredients targeting significant nutritional and therapeutic markets constrained by traditional supply chains. The common thread is LTR’s ability to apply innovation and clinical rigour to deliver differentiated solutions in major markets, building value through first-mover advantage. Next Steps LevOmega’s development pathway will progress through technical validation, pilot-scale production, and ultimately commercial launch, supplying pharmaceutical-grade omega-3 ingredients to pharmaceutical, nutraceutical, and functional food manufacturers. LTR Pharma Executive Chairman, Lee Rodne, said: "This investment highlights LTR’s ability to identify and secure transformative opportunities in large healthcare markets. The omega-3 sector is a multi-billion-dollar market facing supply constraints, and LevOmega offers a scalable, sustainable solution. Our 33% stake, secured through strategic leadership rather than upfront capital, underlines the strength of LTR’s expertise and market position. This partnership allows us to capture upside in the rapidly growing omega-3 market without diluting resources needed for our core therapeutic pipeline.” Source: Science Direct 2022. Sustainable optimisation of the global aquatic omega-3 supply chain could substantially narrow the nutrient gap. 1 - ENDS – 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) This announcement has been approved by the Board of Directors. About LTR Pharma LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets. LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. For further information please contact: Media enquiries Haley Chartres haley@hck.digital Investor enquiries Peter McLennan investors@ltrpharma.com 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)